X4 Pharmaceuticals
One Broadway, 14th Floor
Cambridge
Massachusetts
02142
United States
Website: http://www.x4pharma.com/
235 articles about X4 Pharmaceuticals
-
While the world has largely been focused on the development of vaccines and therapeutics for COVID-19, the U.S. FDA has remained busy lining up potential approvals of medications for other diseases and illnesses.
-
X4 Pharmaceuticals Appoints Art Taveras, Ph.D., as Chief Scientific Officer
11/2/2020
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the appointment of Art Taveras, Ph.D., as Chief Scientific Officer.
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 02, 2020
11/2/2020
X4 Pharmaceuticals, Inc. announced that, on October 30, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.
-
X4 Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020
10/22/2020
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the third quarter ended September 30, 2020
-
X4 Pharmaceuticals Announces Fast Track Designation Granted by the FDA to Mavorixafor for the Treatment of WHIM Syndrome
10/8/2020
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead asset, mavorixafor, for the treatment of adult patients with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome,
-
BioSpace Movers & Shakers, Oct. 2
10/2/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
X4 Pharmaceuticals Expands Board of Directors Through Appointment of Biopharmaceutical Industry Veteran Alison Lawton
10/1/2020
X4 Pharmaceuticals, Inc. announced the expansion of its board of directors with the appointment of Alison Lawton, a biopharmaceutical industry veteran with more than 30 years of experience in a wide range of senior executive and operational roles.
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2020
10/1/2020
X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, announced that, on September 30, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc.
-
X4 Pharmaceuticals to Participate in Three September Virtual Investor Conferences
9/3/2020
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that its management team will participate in the following September virtual investor conferences: Citi 15 th Annual BioPharma Conference, Cantor Fitzgerald Virtual Global Healthcare Conference and Oppenheimer & Co. Fall Healthcare Life Sciences &
-
X4 Pharmaceuticals Announces Publication of Mavorixafor Phase 2 Clinical Data for Treatment of WHIM Syndrome in ‘Blood’ - the Official Journal of the American Society of Hematology
9/2/2020
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the publication of comprehensive safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy data of mavorixafor from an ongoing Phase 2, open-label, dose-escalation and extension study in adult patients with genetically confirmed WHIM
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 01, 2020
9/1/2020
X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, announced that, on August 31, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.
-
X4 Pharmaceuticals to Present and Participate in the Canaccord Genuity’s 40th Annual Growth Conference
8/10/2020
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present and conduct one-on-one meetings during the Virtual Canaccord Genuity 40th Annual Growth Conference on Wednesday, August 12th, 2020
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 05, 2020
8/5/2020
X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, announced that, on August 4, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.
-
X4 Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7/30/2020
Presentation of positive clinical data at EHA 2020 supporting the ongoing Phase 3 trial in WHIM syndrome Initial data expected later this year from Phase 1b clinical trial in Waldenström’s macroglobulinemia Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today reporte
-
X4 Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on July 30, 2020
7/16/2020
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the second quarter ended June 30, 2020, and provide an update on recent business highlights, on July 30, 2020. The Company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss the
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 01, 2020
7/1/2020
X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, announced that, on June 30, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.
-
BioSpace Movers & Shakers, June 12
6/12/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
X4 Pharmaceuticals Presents Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome at EHA 2020
6/12/2020
Sustained efficacy and safety trends observed for up to 28.6 months support ongoing pivotal Phase 3 trial dosing and endpoints, including selection of the measurement of time above threshold for absolute neutrophil count as primary endpoint
-
X4 Pharmaceuticals to Host Conference Call and Webcast to Discuss New Phase 2 Clinical Data for Mavorixafor in WHIM Syndrome to be Presented at 25ᵗʰ European Hematology Association Annual Congress
6/8/2020
X4 Pharmaceuticals, Inc. announced that it will host a conference call and webcast to discuss new clinical efficacy and safety data from the company’s ongoing Phase 2 open-label extension trial of its lead candidate, mavorixafor, in patients with WHIM syndrome.
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 01, 2020
6/1/2020
X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, announced that, on May 29, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.